Dr Martens /£DOCS

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Dr Martens

Dr. Martens, also known as Docs or DMs, is a United Kingdom-based company renowned for its iconic range of footwear, alongside a variety of clothing and accessories. The company, headquartered in Wollaston, Northamptonshire, operates primarily in the footwear manufacturing sector. Established in 1947, Dr. Martens has grown to become a symbol of self-expression and counterculture, distributing its products worldwide under the Dr. Martens brand.

Ticker

£DOCS

Primary listing

LSE

Industry

Textiles, Apparel & Luxury Goods

Employees

2,348

ISIN

GB00BL6NGV24

Dr Martens Metrics

BasicAdvanced
£722M
161.46
£0.00
0.15
£0.02
2.44%

What the Analysts think about Dr Martens

Analyst ratings (Buy, Hold, Sell) for Dr Martens stock.

Bulls say / Bears say

Dr. Martens plans to reduce discounting in key markets, including the U.S., aiming for a return to profit growth in the current financial year. (reuters.com)
The company reported an adjusted pre-tax profit of £34.1 million for the year ending March 31, 2025, surpassing analyst expectations of £30.6 million. (reuters.com)
Berenberg analysts initiated coverage with a 'Buy' rating and a price target of £1.02, highlighting significant potential for global expansion due to strong brand recognition and minimal current market share. (investing.com)
Dr. Martens issued its fourth profit warning in 12 months, citing lackluster demand from U.S. wholesalers and a slower start to the autumn-winter season. (reuters.com)
The company anticipates a single-digit percentage decline in revenue for the year ending March 2024, with full-year core profit expected to be moderately below the bottom end of market expectations. (reuters.com)
Dr. Martens' shares plunged 30% to a record low after flagging a challenging 2025 outlook due to weaker revenues, particularly in the U.S. market. (nbcboston.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

Dr Martens Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Dr Martens Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £DOCS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Aug28
Dr Martens
Dividend·Ex-dividend
Oct8
Dr Martens
Dividend·Payment
£0.017Per share
FAQs